SEATTLE--(BUSINESS WIRE)-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced a strategic transaction to exclusively ...

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it will launch three new products ...

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of its second generation ...

Expanded Functionality to Support COVID-19 Research Immediately Available Through Early Access “ROSALIND offers powerful data analysis capabilities and a unique ability to facilitate collaboration ...

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of a Single Cell Gene ...

More than 35 Abstracts Demonstrate the Value of the nCounter Platform for Targeted Discovery, Biomarker Development and Diagnostic Applications in Cancer Research and Immuno-Oncology NanoString’s New ...

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ...

SEATTLE, March 27, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced ...

NanoString plans to use its IPO proceeds to commercialize the nCounter analyzer and Prosigna test.--Courtesy of NanoString Investor excitement over NanoString's breast cancer diagnostic may not be as ...

NanoString Technologies, Inc. announced the launch of a Single Cell Gene Expression application that provides researchers with a flexible and highly sensitive approach to discovering differences in ...